{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-006509","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.498286+00:00","generated_at":"2026-06-18T16:46:51.603269+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncotelic CMO Fatih Uckun resigns; CRO Seymour Fein assumes CMO role","bullets":["Fatih Uckun, MD, PhD, resigned as Chief Medical Officer effective February 28, 2023.","Seymour Fein, MD, currently Chief Regulatory Officer, will take over as CMO.","Fein will continue as CRO while assuming additional CMO responsibilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-006509","json":"https://secwatch.observer/filing/0001493152-23-006509.json","markdown":"https://secwatch.observer/filing/0001493152-23-006509.md","text":"https://secwatch.observer/filing/0001493152-23-006509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/0001493152-23-006509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T16:46:51.603269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"596a307a47","claim":"Fatih Uckun resigned as Chief Medical Officer at Oncotelic Therapeutics, Inc..","evidence_excerpt":"On February 28, 2023, Fatih Uckun, MD, Ph. D, Chief Medical Officer (“ CMO ”) of Oncotelic Therapeutics, Inc. (the “ Company ”), notified the Company of his resignation as the Company’s CMO, effective February 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/0001493152-23-006509-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"e62ac840cd","claim":"Seymour Fein was appointed as Chief Medical Officer at Oncotelic Therapeutics, Inc..","evidence_excerpt":"Dr. Seymour Fein MD, Chief Regulatory Officer (“CRO”) of the Company, will be taking over the CMO role.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/0001493152-23-006509-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}